Initial versus early switch to targeted therapy during first-line treatment among patients with biomarker-positive advanced or metastatic non-small cell lung cancer in the United States
-
Published:2023
Issue:
Volume:37
Page:100761
-
ISSN:2468-2942
-
Container-title:Cancer Treatment and Research Communications
-
language:en
-
Short-container-title:Cancer Treatment and Research Communications
Author:
Hess Lisa M.ORCID,
Peterson Patrick,
Sugihara Tomoko,
Bhandari Naleen Raj,
Krein Peter M.,
Sireci Anthony
Funder
Eli Lilly and Company
Subject
Cancer Research,Oncology
Reference25 articles.
1. The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer;Melosky;Lung Cancer,2021
2. Complementary roles for tissue-and blood-based comprehensive genomic profiling for detection of actionable driver alterations in advanced NSCLC;Schwartzberg;JTO Clin. Res. Rep.,2022
3. Value of precision medicine in advanced non-small cell lung cancer: Real-world outcomes associated with the use of companion diagnostics;John;Oncologist,2020
4. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial;Nakagawa;Lancet Oncol.,2019
5. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials;Yang;Lancet Oncol.,2015
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献